다우존스 지수

같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.

등록

홈
인베스팅
주식
미국
NASDAQ
Akero Therapeutics Inc (AKRO)
Akero Therapeutics Inc (AKRO) 뉴스

AKRO

Akero Therapeutics (AKRO)

Akero Therapeutics Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:AKRO

1 2 3 4 5 6 7 8 9 10 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2025/02/08	09:54	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:AKRO	Akero Therapeutics Inc
2025/02/08	08:05	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:AKRO	Akero Therapeutics Inc
2025/02/05	23:03	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:AKRO	Akero Therapeutics Inc
2025/01/31	23:14	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:AKRO	Akero Therapeutics Inc
2025/01/31	23:14	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:AKRO	Akero Therapeutics Inc
2025/01/31	06:05	GlobeNewswire Inc.	Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares	NASDAQ:AKRO	Akero Therapeutics Inc
2025/01/30	21:52	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:AKRO	Akero Therapeutics Inc
2025/01/30	10:43	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:AKRO	Akero Therapeutics Inc
2025/01/30	10:43	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:AKRO	Akero Therapeutics Inc
2025/01/30	10:43	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:AKRO	Akero Therapeutics Inc
2025/01/30	07:08	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:AKRO	Akero Therapeutics Inc
2025/01/29	11:30	GlobeNewswire Inc.	Akero Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants	NASDAQ:AKRO	Akero Therapeutics Inc
2025/01/28	11:35	Edgar (US Regulatory)	Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses	NASDAQ:AKRO	Akero Therapeutics Inc
2025/01/28	08:08	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:AKRO	Akero Therapeutics Inc
2025/01/28	08:07	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:AKRO	Akero Therapeutics Inc
2025/01/28	06:53	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:AKRO	Akero Therapeutics Inc
2025/01/28	06:24	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:AKRO	Akero Therapeutics Inc
2025/01/28	06:24	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:AKRO	Akero Therapeutics Inc
2025/01/28	06:23	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:AKRO	Akero Therapeutics Inc
2025/01/28	06:19	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:AKRO	Akero Therapeutics Inc
2025/01/28	06:06	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:AKRO	Akero Therapeutics Inc
2025/01/28	06:01	GlobeNewswire Inc.	Akero Therapeutics Announces Proposed Public Offering of Common Stock	NASDAQ:AKRO	Akero Therapeutics Inc
2025/01/27	22:31	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:AKRO	Akero Therapeutics Inc
2025/01/27	20:30	GlobeNewswire Inc.	Akero Therapeutics Reports Preliminary Topline Results Showing Statistically Significant Reversal of Compensated Cirrhosis (F4) Due to MASH—by Both Completer and ITT Analyses—at Week 96 in Phase 2b SYMMETRY Study	NASDAQ:AKRO	Akero Therapeutics Inc
2025/01/25	06:05	GlobeNewswire Inc.	Akero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH	NASDAQ:AKRO	Akero Therapeutics Inc
2025/01/25	01:01	PR Newswire (US)	Kuehn Law Encourages Investors of Akero Therapeutics, Inc. to Contact Law Firm	NASDAQ:AKRO	Akero Therapeutics Inc
2025/01/13	21:00	GlobeNewswire Inc.	Akero Therapeutics Completes Enrollment of the Double-Blind Portion of the Phase 3 SYNCHRONY Real-World Study Evaluating Efruxifermin (EFX) in Patients with Non-Invasively Diagnosed MASH or MASLD	NASDAQ:AKRO	Akero Therapeutics Inc
2025/01/11	09:38	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:AKRO	Akero Therapeutics Inc
2025/01/07	21:00	GlobeNewswire Inc.	Akero Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference	NASDAQ:AKRO	Akero Therapeutics Inc
2025/01/07	04:08	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:AKRO	Akero Therapeutics Inc

검색 관련기사 보기:NASDAQ:AKRO

1 2 3 4 5 6 7 8 9 10 다음 >>

Invesco QQQ Trust Series 1

US Dollar vs Yen

JP Morgan Chase

Verizon Communications

Health Care Select Sector

Gold vs US Dollar

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관